Jacobs has been chosen to offer engineering services for Mark Cuban Cost Plus Drug Company, PBC’s pharmaceutical facility in Dallas, Texas, the US.

The facility will offer low-cost versions of expensive generic drugs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Mark Cuban Cost Plus Drug Company, PBC awarded contract to Jacobs to finish facility design, right from concept through construction assistance.

Value of the contract has not been disclosed.

The 22,000ft2 sterile fill-finish facility will support formulation, filling and packaging of sterile medicines.

See Also:

Jacobs People & Places Solutions executive vice president Ken Gilmartin said: “We look forward to helping Mark Cuban Cost Plus Drug Company, PBC deliver on its aim to make essential life-enhancing drugs available to more people.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The facility’s innovative design will allow for the production of small product batches considered in short supply by the FDA and those intended for treatment of rare diseases that typically affect a smaller population, known as orphan drugs”

Jacobs claimed that the identification of mechanical enhancements and use of advancements in equipment have been important to cutting down construction and capital costs.

The firm, supporting the delivery programme of just over two years, completed concept and detailed design within 12 months, as against the regular timeframe of 20 to 24 months for sterile fill-facilities.
Construction of the facility is expected to complete in 2022.

———————————————————————————————————————

Image: The flexible fill-finish facility will provide low-cost versions of high-cost generic drugs. Credit: Jacobs.